CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease

NDA FilingALXN1840Positive
AI Analysis

Summary

Monopar Therapeutics has initiated a rolling New Drug Application (NDA) submission for ALXN1840 in Wilson Disease, advancing the candidate toward potential FDA approval.

Outcome Details

Rolling NDA submission initiated

Importance:6/10
Sentiment:
0.60
NDA filingWilson DiseaseRegulatory approval pathway
Related Companies

Read the original article

Published by yahoo_finance on July 22, 2026 12:00 PM

Read Original